Efficacy of trastuzumab in HER-2-positive advanced extramammary Paget’s disease

"Efficacy of trastuzumab in HER-2-positive advanced extramammary Paget’s disease." Expert Opinion on Biological Therapy, 22(5), pp. 673–674

Declaration of interests

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

A reviewer on this manuscript has disclosed involvement with Advanced Accelerator Applications, Alphasites, AstraZeneca, Bayer, Best Doctors, Celldex, Curium, Decision Resources, Inc., Defined Health, Eisai Pharmaceuticals, Exelixis, Inc., Genentech, Inc (Roche Holding), Gerson Lehrman Group, Inc., Guidepoint Global, Health Advances, IPSEN Innovation

Lexicon Pharmaceuticals, Inc., MEDACorp (Leerink Swann & Co), PPD, Inc., Pfizer Inc., QED, Quintiles-Iqvia, Schlesinger Associates, Shionogi Pharma, Society for Immunotherapy of Cancer, Sun Biopharma, Taiho, Ultimate Medical Academy and Xcenda, LLC (AmerisourceBergen Corp). Peer reviewers on this manuscript have no other relevant financial relationships or otherwise to disclose.

Additional information

Funding

This paper was not funded.